ASH 2022

Bispecific antibodies - consolidating data, clinical implications & combinational aspects

Asymptomatic myeloma - what do we really want to achieve?

CAR-T cells - manufacturing, earlier lines & new targets

Treatment of high-risk NDMM patients and MRD-driven deescalation perspectives

Zanu with superior PFS, Pirtobrutinib Update in R/R CLL/SLL, MRD Stopping in CLL

When to treat or not? Watch and wait!? Bispecifics or CART? Do we need a new FLIPI-Score?

Do we treat all MCL identically? New data on Ibru, Tisagenlecleucel and ALR …

Glofi - RCHOP in 1st line, Axi-Cel in 2nd line, TMTV post Axi-Cel, Non-Relapse mortality after CART

NDMM highlights

To transplant or not?

Establish MRI diagnostics early

Maintenance with lenalidomide - how long?

Quadruplet for newly diagnosed high-risk patients

NDMM highlights

MRD-Diagnostik früh etablieren

Isa-KRd bei HR NDMM: Hohe MRD Negativität

Kortikoid-Einsparung bei unfitten Patienten unter DR

Erhaltung mit Lenalidomid - wie lange?

Bispecific antibodies highlights

New CAR-T technologies

Bispecific antibodies

More treatment options with bispecifics emerging!

The future of immunotherapy

New generation CAR-T cell therapy with fast availability

Still biting, Talquetamab?

GPRC5D-immunotherapy

CAR-T cells: new targets and early treatment

Bispecific antibodies highlights

Nye CAR-T-teknologier

Neue Generation der CAR-T Zelltherapie mit schneller Verfügbarkeit

GPRC5D immunterapi

Die Zukunft der Immuntherapie

Bispesifikke antistoffer

CAR-T Zellen: Neue erfolgsversprechende Targets und frühere Anwendung

Bispezifische Antikörper: Weitere Behandlungsoptionen in Sicht

Plasma cells aren't alone!

Smouldering myeloma - potentially curable?

Smouldering Myelom – potentiell heilbar?

Ibrutinib + Ctx replaces autologous stem cell transplantation

VALERIA response-adapted treatment for R/R MCL patients

Glofitamab in R/R mantle cell lymphoma

Early use of anti-CD19 CAR-T (tisacel) plus ibrutinib is highly effective in r/r MCL, including cases with high risk features and/or previous use of BTKi

Glofitamab demonstrates high efficacy in r/r MCL

The R2-Acalabrutinib combination in first-line is highly effective and manageable in MCL, allowing for a time-limited treatment in those cases achieving deeper responses

Ibrutinib added in induction and maintenance improves efficacy and FFS after the first line in younger patients with MCL and challenges the role of autologous transplant consolidation

TRIANGLE - addition of Ibrutinib will improve outcome for younger MCL patients

Ibrutinib combined with chemotherapy could replace ASCT

Fixed-duration Glofitamab produces high quality and durable responses with a favourable toxicity profile in patients with r/r MCL

Ibrutinib + Ctx ersetzt autologe Stammzelltransplantation

Valeria- responsstyrd behandling för recidiverande MCL

Glofitamab en esquema fijo de 12 meses produce respuestas duraderas y de alta calidad en pacientes con LCM en recaída/refractario, con un favorable perfil de seguridad

TRIANGLE- tillägg av ibrutinib förbättrar behandlingsutfall för yngre patienter med MCL

El triplete R2-Acalabrutinib en primera línea es altamente eficaz y manejable en el LCM, permitiendo limitar la duración del tratamiento en los casos con respuestas más profunda

Ibrutinib en inducción y mantenimiento mejora la eficacia y la supervivencia tras la primera línea en pacientes jóvenes con LCM, cuestionando el papel de la consolidación con transplante autólogo

El uso precoz de CAR-T anti-CD19 (tisacel) e ibrutinib es muy eficaz en el LCM en recaída, incluyendo casos de alto riesgo biológico y/o previo uso de iBTK

Glofitamab för recidiverande MCL

Odronextamab in relapsed/refractory follicular lymphoma

A new FLIPI to predict POD24 in follicular lymphoma

Bispecific antibody Epcoritamab s.c. + R2 convincing

Tisagenlecleucel at r/r FL: convincing response more than 2 years

Watch and Wait remains standard of care

Epcoritamab - bispecific antibody highly effective in r/r FL

Is watch & wait still valualble in follicular lymphoma?

Odronextamab nel linfoma follicolare recidivato/refrattario

Epcoritamab-R2 nel linfoma follicolare recidivato/refrattario

Watch and Wait bleibt Standard

Tisagenlecleucel beim r/r FL: Überzeugendes Ansprechen mehr als 2 Jahre

Un nuovo FLIPI per predire la POD24 nel linfoma follicolare

Bispezifischer Antikörper Epcoritamab s.c. + R2 überzeugend

E' ancora valido il watch & wait nel linfoma follicolare?

Alycante - axi-cel in transplant-ineligible R/R DLBCL patients

Two highlight studies in DLBCL treatment

Deux études marquantes dans le traitement du DLBCL

Alycante - axi-cel till patienter med tidigt recidiv av DLBCL, som inte är aktuella för ASCT

Ventricular arrhythmias under combination ibrutinib + venetoclax

Ventrikuläre Arrhythmien unter Kombi Ibrutinib + Venetoclax

Zanubrutinib demonstrates superiority in r/r CLL/SLL

Pirtobrutinib shows activity in pre-treated r/r patients

Is it time to feed our patients?